Multiple sclerosis, now the cure comes home

Rome, June 9 (Adnkronos Health) – The world’s 2.8 million people live with multiple sclerosis, more than 130,000 in Italy alone, where the incidence is about 3,400 new cases a year in the youngest and most productive sector of society (20-40 years), with twice the prevalence of women and men. Patients who can treat neurodegenerative diseases at home. The most recent drug for which Aifa has authorized reimbursement, the first high-efficiency home treatment (Het, High-Effective Therapy) that is self-administered at home once a month, is a step forward in the provision of treatments between domestic walls. This is reported in an article published in ‘Alliats for Health’, the portal dedicated to medical-scientific information created by Novartis.

Home care is a particularly important aspect given that multiple sclerosis, a disease of the central nervous system, impairs the normal functioning of the brain, optic nerves and spinal cord through inflammation and loss of nervous tissue, causing time to varying degrees physical, emotional and social disability. Early diagnosis is not easy because the disease has very varied symptoms that can also vary over time in both duration and intensity. Among the most common: visual disturbances, fatigue and exhaustion (fatigue), difficulty balancing and walking, lack of strength, tingling and sensitivity problems.

About 85% of people initially diagnosed have the recurrent form of remission, which is characterized by acute episodes of illness (relapses) alternating with periods of total or partial well-being (remissions), and for which there is now a new high efficiency home care. (Het).

There are three forms of multiple sclerosis: mainly progressive (Smpp), recurrent-remission (Smrr) and secondary progressive (Smsp). The latter derives from an initial course of Smrr and is characterized by physical and cognitive alterations over time, in the presence or absence of relapses, leading to an accumulation of neurological disability. In the field of multiple sclerosis – we read in the article – today we reach the goal of having the right therapies for the different stages of the disease: from its manifestations in pediatric age to the more advanced stages. of its progression.

Specifically, the drug for which Aifa recently approved the reimbursement by the National Health Service responds to a significant unmet clinical need of people living with recurrent multiple sclerosis because it is the first highly effective therapy, targeting B lymphocytes. , which can be easy to self-administer once a month at home. The possibility of doing the treatment at home, with great flexibility, is a considerable advantage in terms of quality of life and direct and indirect costs for the NHS: thanks to home therapy, in fact, patients can significantly reduce the time required. cope with treatment, with a favorable effect on social and working life.

The home, for multiple sclerosis, is increasingly a place of care, as also foreseen by the PNR, not only of treatments, but also of services that can help the patient to manage his pathology. In fact, only for people with multiple sclerosis, television models of patients have been developed, artificial intelligence solutions have been promoted to monitor various parameters, and free drug delivery and support services have been created. for medical staff.

Unlike other neurological and neurodegenerative diseases, which mainly affect the elderly population, multiple sclerosis often occurs between the ages of 20 and 30, in 10% of cases at age 18 with profound social implications because it affects the education, professional life, relationships and, in general, about autonomy, since over time the patient may require continued care.

The full article is available at:

Leave a Comment